Literature DB >> 389103

The usefulness of theophylline in nonasthmatic airway obstruction.

R Schmidt, S Altschuler.   

Abstract

This study evaluated the effectivness of oral bronchodilator therapy using theophylline in patients with nonreversible chronic obstructive pulmonary disease. Twelve chronic obstructive pulmonary disease patients were entered into a doubleblind crossover study using either active drug theophylline in 200 mg capsules (Elixophyllin) or placebo for 3 months, followed by 3 months of the alternate capsule. At baseline and monthly visits, data were recorded, including history, physical examination, and pulmonary function testing. Clinically, 7 of 11 patients responded favorably to theophylline, 3 were unchanged, and 1 improved on placebo. Comparison of each sign and symptom individually revealed no statistically significant differences. Pulmonary function (FEV1 and FVC) showed slight deterioration with placebo, but not with active drug therapy. These findings suggest that nonasthmatic patients may improve clinically during theophylline therapy whereas their pulmonary function may deteriorate during placebo therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389103     DOI: 10.1177/000331977903001103

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease.

Authors:  G Fink; C Kaye; J Sulkes; U Gabbay; S A Spitzer
Journal:  Thorax       Date:  1994-04       Impact factor: 9.139

2.  A meta-analysis on the efficacy of oral theophylline in patients with stable COPD.

Authors:  Néstor A Molfino; Peter Zhang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 3.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.